Ultragenyx Pharmaceutical reported $1.19B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Insmed USD 2.36B 119.12M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Kyowa Hakko Kirin JPY 1.08T 10.94B Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Moderna USD 12.14B 125M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025